Completed PHASE3 INTERVENTIONAL 1-arm NCT01002898

Ritonavir-boosted Lopinavir Monotherapy

Treatment Outcomes and Plasma Level of Ritonavir-boosted Lopinavir Monotherapy Among HIV-infected Patients Who Had Non-nucleoside Reverse Transcriptase Inhibitor (NRTI) and NNRTI Failure: A Pilot Study

Sponsor: Bamrasnaradura Infectious Diseases Institute

Conditions HIV

Interventions lopinavir/ritonavir soft gel capsule

Updated 5 times since 2017 Last updated: Nov 10, 2011 Started: Apr 30, 2007 Primary completion: Feb 28, 2011 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HIV, this trial is completed. The trial is conducted by Bamrasnaradura Infectious Diseases Institute and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bamrasnaradura Infectious Diseases Institute

Data source: Bamrasnaradura Infectious Diseases Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nonthaburi, Thailand